Table 2 Clinical, cytogenetic, and molecular characteristics of all clusters

From: Molecular patterns identify distinct subclasses of myeloid neoplasia

Variables

All

MC1

MC2

MC3

MC4

MC5

MC6

MC7

MC8

MC9

MC10

MC11

MC12

MC13

MC14

P-value

Total population

3588

201

920

76

313

107

301

225

236

219

143

121

130

391

205

 

 Test cohort

718 (20)

39 (19)

178 (19)

12 (16)

58 (19)

18 (17)

58 (19)

54 (24)

55 (23)

37 (17)

31 (22)

20 (17)

26 (20)

87 (22)

45 (22)

 

 Training cohort

2870 (80)

162 (80)

742 (81)

64 (84)

255 (82)

89 (83)

243 (81)

171 (76)

181 (77)

182 (83)

112 (78)

101 (84)

104 (80)

304 (78)

45 (22)

 

Age, median (IQR)

72 (64–77)

74 (67–80)

69 (59–76)

75 (69–82)

72 (66–78)

72 (65–78)

74 (68-78)

68 (59-74)

74 (68–80)

72 (64–77)

74 (70–78)

70 (62–75)

75 (69–80)

71 (63–77)

71 (63–77)

<0.001

Gender

               

<0.001

 Male

2143 (60)

131 (65)

519 (56)

60 (79)

182 (58)

72 (67)

203 (67)

135 (60)

71 (30)

163 (74)

76 (53)

70 (58)

91 (70)

217 (56)

153 (75)

 

 Female

1444 (40)

70 (35)

401 (44)

16 (21)

131 (42)

35 (33)

35 (33)

90 (40)

165 (70)

56 (26)

67 (47)

51 (42)

39 (30)

174 (45)

51 (25)

 

Labs

  WBC (109/L)

4 (3–11)

6 (3–14)

5 (3–12)

7 (4–11)

6 (4–9)

5 (3–10)

5 (3–13)

5 (3–12)

4 (3–6)

6 (3–22)

5 (4–7)

4 (3–19)

10 (3–25)

3 (2–8)

6 (3–13)

<0.001

  Hb(g/dL)

10 (9–11)

9 (8–11)

10 (9–12)

10 (9–12)

10 (9–11)

10 (9–11)

11 (10–13)

10 (9–11)

9 (8–10)

10 (9–11)

10 (9–11)

9 (8–10)

10 (9–12)

9 (8–10)

10 (8–11)

<0.001

  Platelet (109/L)

112 (50–240)

87 (32–163)

104 (54–221)

118 (68–160)

307 (184–420)

92 (39–171)

100 (66–154)

111 (46–191)

217 (77–321)

96 (38–220)

232 (146–333)

48 (24–131)

83 (47–131)

76 (30–102)

109 (40–235)

<0.001

 BM blast %

4 (2–13)

12 (4–37)

4 (1–14)

9 (3–12)

2 (1–4)

3 (1–6)

6 (3–12)

3 (1–7)

4 (2–5)

7 (3–14)

2 (1–4)

8 (4–24)

8 (3–14)

12 (3–22)

5 (1–29)

 

Diagnosis

               

<0.001

 LR-MDS

2079 (58)

73 (36)

566 (62)

37 (49)

268 (86)

77 (72)

152 (51)

147 (65)

184 (78)

96 (44)

112 (78)

46 (38)

68 (52)

150 (38)

103 (50)

 

 HR-MDS

774 (22)

50 (25)

148 (16)

28 (37)

27 (9)

14 (13)

116 (39)

49 (22)

21 (9)

86 (39)

26 (18)

33 (27)

42 (32)

111 (28)

23 (11)

 

 s-AMLa

735 (21)

78 (39)

206 (22)

11 (15)

18 (6)

16 (15)

33 (11)

29 (13)

31 (13)

37 (17)

5 (4)

42 (35)

20 (15)

130 (33)

79 (39)

 

Diagnosis, %

  MDS-SLDb

14

8

16

16

41

19

6

14

0.4

6

26

3

5

10

19

<0.001

  MDS-MLDb

22

12

22

16

38

35

19

22

7

19

50

12

18

17

19

<0.001

  5q syndrome

5

0

0.1

0

0

0

0

0.4

67

0

0

0

1

1

0

<0.001

  MDS/MPN

10

11

18

7

5

18

5

14

2

10

2

8

6

6

9

<0.001

  CMML 1/2

7

6

4

13

2

1

24

11

1

12

1

9

25

1

2

<0.001

  MDS-EB1

10

10

10

18

6

8

19

9

4

19

13

15

8

9

7

<0.001

  MDS-EB2

10

13

6

15

2

5

15

10

4

16

4

10

22

19

4

<0.001

  Othersc

2

1

2

1

1

1

1

7

0.4

1

0

9

1

4

2

<0.001

Cytogenetics

 Normal

2023 (57)

1 (1)

920 (100)

0 (0)

313 (100)

0 (0)

300 (99.7)

0 (0)

0 (0)

217 (99)

142 (99)

0 (0)

130 (100)

0 (0)

0 (0)

 

 Abnormal

1548 (43)

200 (100)

0 (0)

76 (100)

0 (0)

106 (100)

1 (0.3)

221 (100)

236 (100)

2 (1)

1 (1)

121 (100)

0 (0)

391 (100)

205 (100)

 

Number of MT

  0

825 (23)

40 (20)

446 (49)

0 (0)

0 (0)

22 (21)

0 (0)

39 (17)

75 (32)

0 (0)

0 (0)

34 (28)

0 (0)

92 (24)

77 (38)

 

  1–2

1666 (46)

70 (35)

366 (40)

45 (59)

235 (75)

55 (51)

162 (54)

109 (48)

130 (55)

57 (26)

63 (44)

54 (36)

7 (5)

219 (56)

104 (51)

 

  3–4

813 (23)

57 (28)

77 (8)

26 (34)

68 (22)

21 (20)

117 (39)

50 (22)

26 (11)

114 (52)

70 (49)

32 (26)

71 (55)

64 (16)

20 (10)

 

  >4

284 (8)

34 (17)

31 (3)

5 (7)

10 (13)

9 (8)

22 (7)

27 (12)

5 (2)

48 (22)

10 (7)

1 (1)

52 (40)

16 (4)

4 (2)

 
  1. a sAML is defined as acute myeloid leukemia evolving from MDS or MDS/MPN, or diagnosed in the setting of MDS related cytogenetic abnormalities. High risk MDS (HR-MDS) was defined based on ≥ 5% bone marrow (BM) blast. Low risk MDS (LR-MDS) was defined based on BM blast <5%. b MDS-SLD-RS and MDS-MLD-RS are included in this group. c MDS/MPN-RS-T and MDS-U are included in this group. IQR interquartile range, WBC white blood cell count, MDS myelodysplastic syndrome, sAML secondary acute myeloid leukemia, BM bone marrow, SLD single lineage dysplasia, MLD multi-lineage dysplasia, CMML chronic myelomonocytic leukemia, MPN myeloproliferative neoplasm, EB excess blast, MT mutations. Two-sided nonparametric Wilcoxon matched-pairs signed rank test and Chi square test were used to compare differences across groups for numerical and categorical variables respectively. P value ≤ 0.05 was considered statistically significant.
Back to article page